Italia markets closed

CPRX Jun 2024 7.500 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,25000,0000 (0,00%)
Alla chiusura: 09:59AM EDT
Schermo intero
Chiusura precedente0,2500
ApertoN/D
Denaro0,0000
Domanda0,0000
Prezzo d'esercizio7,50
Scadenza2024-06-21
Min-Max giorno0,2500 - 0,2500
Contratto - Min-MaxN/D
VolumeN/D
Open Interest1
  • GlobeNewswire

    Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida

    CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that Patrick J. McEnany, Founder, Chairman and CEO of Catalyst, has been bestowed the 2023 Lifetime Achievement Award by BioFlorida at their Annual Meeting last Friday. This prestigious award highlights Mr. McEnany's outstanding accomplishments, unwavering commitment to rare disease patients, dedication to Cat

  • GlobeNewswire

    Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®

    The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome U.S. FDA Assigned Target Action Date of June 4, 2024 CORAL GABLES, Fla., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced that the U.S. Food and Drug Administration ("FDA" or "Agency") has accepted for review the Company's supplemental New Drug Application ("sNDA") to increase the indicate

  • GlobeNewswire

    Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference

    CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the Catalyst’s senior management team, will participate in the 2023 Cantor Global Healthcare Conference which will be held on Se